# IBD-Specific Cognitive Behavioral Therapy: Sustainability of Effect After Three Years

**Authors:** Floor Bennebroek Evertsz’, Florentine L. S. Goes, Pieter C. F. Stokkers, Robbert Sanderman, Mathilde G. E. Verdam, Mirjam Sprangers, Claudi L. Bockting

PMC · DOI: 10.32872/cpe.14717 · Clinical Psychology in Europe · 2025-08-29

## TL;DR

IBD-specific cognitive behavioral therapy (CBT) improves quality of life and mental health in IBD patients, with benefits lasting up to three years after treatment.

## Contribution

This study demonstrates the long-term sustainability of IBD-specific CBT effects on mental health and quality of life.

## Key findings

- Three years post-treatment, the chance of having a DSM disorder decreased by 48%.
- Significant improvements in IBD-specific and generic QoL, anxiety, and depression were sustained.
- Patients showed further improvement in QoL even after therapy completion.

## Abstract

‘Inflammatory Bowel Disease (IBD)-specific-Cognitive-Behavioral Therapy’ (CBT) is effective in improving Quality of Life (QoL) and in decreasing anxiety and depression in IBD-patients with poor mental QoL, one month after completing CBT. Main aim was to examine the sustainability of treatment effects up to three years after treatment with CBT.

Participants (n = 118) of a previously conducted randomized-control-study on the effects of ‘IBD-specific-CBT’ for IBD-patients were contacted for a long-term follow-up assessment on main outcomes: generic and IBD-specific-QoL (SF-36, IBDQ), anxiety and depression (HADS, CES-D) and DSM-IV disorders (SCID-I). Change over time was examined with multilevel-regression-analyses.

Three years after finishing ‘IBD-specific-CBT’, 61 IBD-patients (response rate 52%) completed the follow-up SCID-I assessment and 52 patients (response rate 44%) completed the assessments for symptomatology. There were no differences between dropouts and participants at three year follow-up, except for a longer disease duration in dropouts. At three-year follow-up the chance of patients having a DSM-disorder significantly decreased with an estimated 48% (from 87% at baseline to 38% at follow-up). Multilevel analyses showed a significant improvement between baseline (n = 118) and follow-up measurements (n = 52) on outcomes: IBDQ-Total (Cohen’s d effect-size = .89), SF-36 Physical (d = .54), and SF-36 Mental (d = .69), HADS-A (d = -.77), HADS-D (d = -.65) and CES-D (d = -.55); all p < .01. QoL outcomes showed further improvement between completion (n = 90 for IBD-specific QoL and n = 91 for generic QoL) and follow-up measurements, with significant improvements for IBDQ-Total (d = 0.31) and SF-36 Physical (d = 0.32).

Sustainable positive effects of ‘IBD-specific-CBT’ for IBD-patients with poor mental QoL were found and the prevalence of mental conditions substantially decreased over three year follow-up.

IBD-specific-CBT showed lasting benefits on QoL, anxiety, and depression three years post-treatment.Patients further improved, even after completion of therapy regarding IBD-specific QoL and generic physical QoL.Comorbid psychiatric disorders at baseline had decreased at long-term follow-up three years after ending ‘IBD-specific-CBT’.Larger studies are needed to confirm these findings.

IBD-specific-CBT showed lasting benefits on QoL, anxiety, and depression three years post-treatment.

Patients further improved, even after completion of therapy regarding IBD-specific QoL and generic physical QoL.

Comorbid psychiatric disorders at baseline had decreased at long-term follow-up three years after ending ‘IBD-specific-CBT’.

Larger studies are needed to confirm these findings.

## Linked entities

- **Diseases:** Inflammatory Bowel Disease (MONDO:0005265), anxiety (MONDO:0005618), depression (MONDO:0002050)

## Full-text entities

- **Genes:** CECR (cat eye syndrome chromosome region) [NCBI Gene 1055] {aka CES}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** Psychiatric (MESH:D001523), Anxiety (MESH:D001007), somatic illness (MESH:D013001), inflammation (MESH:D007249), steroid resistance (MESH:D009404), PTSD (MESH:D013313), DSM-disorder (MESH:D009358), SCID (MESH:D053632), anxiety disorders (MESH:D001008), mood disorders (MESH:D019964), psychotic disorder (MESH:D011618), COVID (MESH:D000086382), CD (MESH:D003424), mental health (OMIM:603663), alcohol related disorder (MESH:D019973), UC (MESH:D003093), adjustment disorders (MESH:D000275), Depression (MESH:D003866), IBD (MESH:D015212), DSM-IV (MESH:D006011), eating disorder (MESH:D001068)
- **Species:** Homo sapiens (human, species) [taxon 9606], gut metagenome (species) [taxon 749906]
- **Mutations:** DELTA

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12918453/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12918453/full.md

---
Source: https://tomesphere.com/paper/PMC12918453